BRPI0910461B8 - hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso - Google Patents

hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Info

Publication number
BRPI0910461B8
BRPI0910461B8 BRPI0910461A BRPI0910461A BRPI0910461B8 BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8 BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8
Authority
BR
Brazil
Prior art keywords
production method
stimulating hormone
follicle stimulating
pharmaceutical composition
recombinant follicle
Prior art date
Application number
BRPI0910461A
Other languages
English (en)
Portuguese (pt)
Inventor
Plaksin Daniel
Cottingham Ian
Boyd White Richard
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910461(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of BRPI0910461A2 publication Critical patent/BRPI0910461A2/pt
Publication of BRPI0910461A8 publication Critical patent/BRPI0910461A8/pt
Publication of BRPI0910461B1 publication Critical patent/BRPI0910461B1/pt
Publication of BRPI0910461B8 publication Critical patent/BRPI0910461B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0910461A 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso BRPI0910461B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (4)

Publication Number Publication Date
BRPI0910461A2 BRPI0910461A2 (pt) 2018-03-27
BRPI0910461A8 BRPI0910461A8 (pt) 2018-10-16
BRPI0910461B1 BRPI0910461B1 (pt) 2021-02-23
BRPI0910461B8 true BRPI0910461B8 (pt) 2021-05-25

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910461A BRPI0910461B8 (pt) 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Country Status (29)

Country Link
US (6) US8951967B2 (cg-RX-API-DMAC7.html)
EP (7) EP3098234B1 (cg-RX-API-DMAC7.html)
JP (7) JP2011519359A (cg-RX-API-DMAC7.html)
KR (5) KR102108377B1 (cg-RX-API-DMAC7.html)
CN (3) CN105906702A (cg-RX-API-DMAC7.html)
AR (1) AR071479A1 (cg-RX-API-DMAC7.html)
AU (5) AU2009237479B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910461B8 (cg-RX-API-DMAC7.html)
CA (1) CA2725257A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115413T1 (cg-RX-API-DMAC7.html)
DK (6) DK3144318T3 (cg-RX-API-DMAC7.html)
ES (5) ES2610277T3 (cg-RX-API-DMAC7.html)
FI (4) FI3098234T3 (cg-RX-API-DMAC7.html)
FR (3) FR17C1020I2 (cg-RX-API-DMAC7.html)
HR (5) HRP20241187T1 (cg-RX-API-DMAC7.html)
HU (9) HUE068565T2 (cg-RX-API-DMAC7.html)
IL (2) IL208538A (cg-RX-API-DMAC7.html)
LT (8) LT3045471T (cg-RX-API-DMAC7.html)
MX (3) MX2010011343A (cg-RX-API-DMAC7.html)
NO (4) NO2017025I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ588381A (cg-RX-API-DMAC7.html)
PL (6) PL3144318T3 (cg-RX-API-DMAC7.html)
PT (6) PT3098234T (cg-RX-API-DMAC7.html)
RU (3) RU2537268C2 (cg-RX-API-DMAC7.html)
SA (1) SA109300228B1 (cg-RX-API-DMAC7.html)
SI (6) SI4015527T1 (cg-RX-API-DMAC7.html)
TW (1) TWI488640B (cg-RX-API-DMAC7.html)
WO (1) WO2009127826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007373B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HRP20150968T4 (hr) 2010-09-29 2023-11-10 Ferring B.V. Pripravak za uporabu za liječenje neplodnosti
KR101898302B1 (ko) 2010-10-15 2018-09-13 제이씨알 파마 가부시키가이샤 당사슬의 비환원 말단이 만노오스 잔기인 당 단백질의 제조 방법
CA2831486A1 (en) * 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2013161958A1 (ja) * 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
ES2784625T3 (es) 2015-04-17 2020-09-29 Ferring Bv FSH para el tratamiento de la infertilidad
EP3313859B1 (en) 2015-06-26 2019-11-20 Ferring BV Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
AR112541A1 (es) 2017-09-01 2019-11-06 Ferring Bv Composición para estimulación ovárica controlada con hef recombinante
EP3787667B1 (en) 2018-04-30 2025-03-26 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
US20250241993A1 (en) 2022-04-01 2025-07-31 Ferring B.V. Mixed protocol for treatment of infertility
US20250333466A1 (en) 2022-05-26 2025-10-30 Ferring B.V. Compositions and methods for treatment of infertility in males
AU2023302100A1 (en) 2022-07-08 2025-01-02 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
TW202504578A (zh) 2023-07-20 2025-02-01 荷蘭商輝凌責任有限公司 緩釋載藥微粒

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
EP1621549A3 (en) * 2001-10-22 2006-03-01 Applied Research Systems ARS Holding N.V. Compositions of fsh with high sialylation degree and their use for the preparation of medicinaments
BR0213402A (pt) 2001-10-29 2004-10-13 Crucell Holland Bv Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
CA2468957C (en) 2001-12-07 2011-07-12 Crucell Holland B.V. Methods of propagation of influenza virus in cell lines over expressing sialyl transferases
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
DK1711834T3 (da) 2004-02-04 2010-11-29 Centre Nat Rech Scient Fremgangsmåde til screening af glycoform-specifikke antistoffer
CN1926242B (zh) 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HRP20150968T4 (hr) 2010-09-29 2023-11-10 Ferring B.V. Pripravak za uporabu za liječenje neplodnosti
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
US20170035854A1 (en) 2014-04-18 2017-02-09 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
PL3144318T3 (pl) 2021-02-08
AU2017204259B2 (en) 2017-08-17
HUE068565T2 (hu) 2025-01-28
US9771407B2 (en) 2017-09-26
AU2014203277A1 (en) 2014-07-24
EP3098234A1 (en) 2016-11-30
FR25C1025I1 (fr) 2025-09-19
AU2017225020A1 (en) 2017-09-28
JP2022031652A (ja) 2022-02-22
KR102108377B1 (ko) 2020-05-08
PT3045471T (pt) 2017-06-14
FI4015527T3 (fi) 2025-04-29
KR20160056960A (ko) 2016-05-20
PT2808340T (pt) 2016-11-21
DK3098234T3 (da) 2024-10-21
CA2725257A1 (en) 2009-10-22
RU2682270C2 (ru) 2019-03-18
JP6762916B2 (ja) 2020-09-30
EP2808340B1 (en) 2016-08-17
RU2537268C2 (ru) 2014-12-27
AU2017204258B2 (en) 2017-08-17
PT3098234T (pt) 2024-10-21
SI3144318T1 (sl) 2020-12-31
HUS1700024I1 (hu) 2017-06-28
PT2268666E (pt) 2014-06-25
US20180079794A1 (en) 2018-03-22
HRP20140535T1 (hr) 2014-07-18
NO2017025I1 (no) 2017-06-06
HRP20170958T1 (hr) 2017-09-22
PT4015527T (pt) 2025-04-10
US9546204B2 (en) 2017-01-17
IL208538A0 (en) 2010-12-30
EP4015527B1 (en) 2025-01-22
ES2610277T3 (es) 2017-04-26
RU2014141994A (ru) 2016-05-10
JP6486310B2 (ja) 2019-03-20
SI3098234T1 (sl) 2024-10-30
AU2009237479B2 (en) 2014-05-15
MX348622B (es) 2017-06-22
LT2808340T (lt) 2016-11-10
SI2268666T1 (sl) 2014-07-31
US20150065695A1 (en) 2015-03-05
HRP20241187T1 (hr) 2024-12-06
US8951967B2 (en) 2015-02-10
FR17C1020I1 (cg-RX-API-DMAC7.html) 2020-04-10
HUE033830T2 (en) 2018-01-29
PL2268666T3 (pl) 2014-08-29
EP2722339A1 (en) 2014-04-23
FIC20250003I1 (fi) 2025-01-15
LTPA2017029I1 (lt) 2017-10-10
HK1199039A1 (en) 2015-06-19
AU2014203277B2 (en) 2017-04-06
US20110105398A1 (en) 2011-05-05
TW200948378A (en) 2009-12-01
PL3098234T3 (pl) 2025-01-07
JP7316905B2 (ja) 2023-07-28
KR20190092608A (ko) 2019-08-07
HUE030652T2 (en) 2017-05-29
LT4015527T (lt) 2025-04-10
HUS1700025I1 (hu) 2017-06-28
EP2268666A1 (en) 2011-01-05
WO2009127826A1 (en) 2009-10-22
JP2011519359A (ja) 2011-07-07
NZ588381A (en) 2012-05-25
CY1115413T1 (el) 2017-01-04
HRP20250313T1 (hr) 2025-05-09
US11952407B2 (en) 2024-04-09
AU2009237479A1 (en) 2009-10-22
AU2017204258A1 (en) 2017-07-20
HUS2500029I1 (hu) 2025-07-28
EP3144318B1 (en) 2020-09-23
JP2015120696A (ja) 2015-07-02
LT3045471T (lt) 2017-07-10
AR071479A1 (es) 2010-06-23
LTPA2017018I1 (lt) 2017-06-26
PL2808340T3 (pl) 2017-02-28
JP2020040956A (ja) 2020-03-19
LT3098234T (lt) 2024-09-10
ZA201007373B (en) 2011-06-29
FR17C1020I2 (fr) 2020-04-10
PL3045471T3 (pl) 2017-10-31
SA109300228B1 (ar) 2014-04-08
ES3023526T3 (en) 2025-06-02
HUE030652T4 (en) 2017-09-28
ES2468318T3 (es) 2014-06-16
KR20110005863A (ko) 2011-01-19
BRPI0910461A8 (pt) 2018-10-16
BRPI0910461A2 (pt) 2018-03-27
HUS2500008I1 (hu) 2025-02-28
US20240327487A1 (en) 2024-10-03
FR25C1003I1 (fr) 2025-02-28
DK2268666T3 (da) 2014-05-12
HK1146284A1 (en) 2011-05-20
BRPI0910461B1 (pt) 2021-02-23
ES2629392T3 (es) 2017-08-09
US20160347811A1 (en) 2016-12-01
KR20180095140A (ko) 2018-08-24
MX355457B (es) 2018-04-19
KR101622944B1 (ko) 2016-05-23
DK3144318T3 (da) 2020-12-07
EP2808340A1 (en) 2014-12-03
IL208538A (en) 2014-03-31
US10995128B2 (en) 2021-05-04
PT3144318T (pt) 2020-11-04
RU2010141908A (ru) 2012-05-27
EP3144318A1 (en) 2017-03-22
EP3098234B1 (en) 2024-07-31
AU2017204259A1 (en) 2017-07-20
NO2025006I1 (no) 2025-01-16
FI3098234T3 (fi) 2024-10-31
JP2018021037A (ja) 2018-02-08
RU2745557C1 (ru) 2021-03-29
RU2014141994A3 (cg-RX-API-DMAC7.html) 2018-05-28
NO2025032I1 (no) 2025-07-14
US20210332099A1 (en) 2021-10-28
SI2808340T1 (sl) 2016-12-30
HRP20161520T1 (hr) 2016-12-30
EP2268666B1 (en) 2014-03-12
EP4015527A1 (en) 2022-06-22
NO2017050I1 (no) 2017-09-28
DK4015527T3 (da) 2025-04-14
KR20170110741A (ko) 2017-10-11
LTPA2025525I1 (cg-RX-API-DMAC7.html) 2025-07-25
ES2989729T3 (es) 2024-11-27
EP3045471A1 (en) 2016-07-20
TWI488640B (zh) 2015-06-21
DK2808340T3 (en) 2016-12-05
JP2017060476A (ja) 2017-03-30
JP2024038000A (ja) 2024-03-19
CN105906702A (zh) 2016-08-31
AU2017225020B2 (en) 2019-11-14
IL230571A (en) 2015-11-30
SI3045471T1 (sl) 2017-07-31
LTPA2025505I1 (cg-RX-API-DMAC7.html) 2025-02-10
CN105906703A (zh) 2016-08-31
RU2745557C3 (ru) 2021-12-10
CN102066414A (zh) 2011-05-18
HUE071059T2 (hu) 2025-07-28
FIC20250025I1 (fi) 2025-07-11
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
AU2014203277C1 (en) 2017-07-27
EP3045471B1 (en) 2017-03-29
DK3045471T3 (en) 2017-06-26
HUS1700036I1 (hu) 2017-10-30
SI4015527T1 (sl) 2025-05-30

Similar Documents

Publication Publication Date Title
BRPI0910461B8 (pt) hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
TN2012000478A1 (en) Long - acting formulations of insulins
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
BR112015014760A2 (pt) complexo de zinco-aminoácido com cisteína
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BR112015032559A8 (pt) cerâmica odontológica de zircônia, artigo odontológico, e seu método de fabricação
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
WO2012127501A3 (en) Composition for improving endometrial thickness during ovarian stimulation
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
CR10092A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y su uso
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
MX2015017540A (es) Formulacion de relacion fija de insulina glargina-lixisenatida.
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF